Crystalline form of aryl aniline beta-2 adrenergic receptor agonist
The invention provides crystalline solvate forms of a salt of a novel β2 adrenergic receptor agonist. The invention also provides pharmaceutical compositions comprising the solvate forms, formulations containing the pharmaceutical compositions,
-
Page 3-4; 11
(2008/06/13)
Aryl aniline beta2 adrenergic receptor agonists
The invention provides novel β2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2 adrenergic
-
(2008/06/13)
Aryl aniline beta2 adrenergic receptor agonists
The invention provides novel β2 adrenergic receptor agonist compounds of formula (I): wherein R1-R13 and w have any of the values described in the specification. The invention also provides combinations of such compounds and other therapeutic agents, pharmaceutical compositions comprising such compounds and combinations, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.
-
Page 50-51
(2008/06/13)
More Articles about upstream products of 530084-78-7
Get Best Price for530084-78-7N-[2-[4-[(3-phenyl-4-methoxyphenyl)amino]phenyl]ethyl]-(R)-2-hydroxy-2-(8-benzyloxy-1,2-dihydro-2-oxoquinolin-5-yl)ethylamine